Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Rajasthan Royals launch ANOTHER bid to invest in cash
Union push pits the United Farm Workers against a major California agricultural business
Bette Midler reveals she regrets not SUING co
Syrian first lady Asma Assad diagnosed with leukemia, president's office says
Seeds from China's space station applied in breeding experiments
Beyond Meat urges investors to look past bumpy Q1, says new US burger could reignite sales
Turnbull scores twice as Toronto cruises past Minnesota 4
Biden to release 1 million barrels of gasoline in bid to lower prices at pump
Three men sentenced to life in prison for killing family in Washington state
Adela Cernousek of Texas A&M wins NCAA individual golf title for first collegiate win
Cheryl Fergison's toyboy husband Yassine Al